-
How Five Prime's Bristol-Myers Partnership Helps Investors
Monday, October 19, 2015 - 3:35pm | 356Read More...Five Prime Therapeutics Inc (NASDAQ: FPRX) shares have been volatile in 2015 and are up 104 percent since October 12. Oppenheimer’s Christopher Marai maintained an Outperform rating on the company, while raising the price target from $45 to $48. The company’s partnership with Bristol-...
